The first IgE antibody trial triggers a distinct and potent immune response, which makes it extremely important from a scientific standpoint. After this fruitful trial, researchers intend to carry out further clinical development of MOv18 IgE in order to guarantee its safety in patients. The ultimate objective is to target cancer cells with a comparable level of efficiency, providing patients with a fresh therapy option.
For more: https://non-igg-ab.creativ...